504 related articles for article (PubMed ID: 24022428)
1. HMG CoA reductase inhibitors (statins) for dialysis patients.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Nigwekar SU; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD004289. PubMed ID: 24022428
[TBL] [Abstract][Full Text] [Related]
2. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
3. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
Palmer SC; Navaneethan SD; Craig JC; Perkovic V; Johnson DW; Nigwekar SU; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005019. PubMed ID: 24470059
[TBL] [Abstract][Full Text] [Related]
4. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702
[TBL] [Abstract][Full Text] [Related]
5. HMG CoA reductase inhibitors (statins) for dialysis patients.
Navaneethan SD; Nigwekar SU; Perkovic V; Johnson DW; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2009 Jul; (3):CD004289. PubMed ID: 19588351
[TBL] [Abstract][Full Text] [Related]
6. HMG CoA reductase inhibitors (statins) for dialysis patients.
Navaneethan SD; Nigwekar SU; Perkovic V; Johnson DW; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2009 Apr; (2):CD004289. PubMed ID: 19370598
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
8. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
9. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Navaneethan SD; Pansini F; Perkovic V; Manno C; Pellegrini F; Johnson DW; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2009 Apr; (2):CD007784. PubMed ID: 19370693
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Statins for the primary prevention of cardiovascular disease.
Taylor F; Huffman MD; Macedo AF; Moore TH; Burke M; Davey Smith G; Ward K; Ebrahim S
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004816. PubMed ID: 23440795
[TBL] [Abstract][Full Text] [Related]
12. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease.
Nistor I; Palmer SC; Craig JC; Saglimbene V; Vecchio M; Covic A; Strippoli GF
Cochrane Database Syst Rev; 2015 May; 2015(5):CD006258. PubMed ID: 25993563
[TBL] [Abstract][Full Text] [Related]
13. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
Navaneethan SD; Perkovic V; Johnson DW; Nigwekar SU; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2009 Apr; (2):CD005019. PubMed ID: 19370615
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering agents for nephrotic syndrome.
Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
[TBL] [Abstract][Full Text] [Related]
15. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
Hahn D; Cody JD; Hodson EM
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
[TBL] [Abstract][Full Text] [Related]
16. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
[TBL] [Abstract][Full Text] [Related]
17. HMG CoA reductase inhibitors (statins) for dialysis patients.
Navaneethan SD; Shrivastava R
Cochrane Database Syst Rev; 2004 Oct; (4):CD004289. PubMed ID: 15495097
[TBL] [Abstract][Full Text] [Related]
18. Psychosocial interventions for preventing and treating depression in dialysis patients.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Rabindranath KS; Strippoli GF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004542. PubMed ID: 31789430
[TBL] [Abstract][Full Text] [Related]
19. HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
Lewicki M; Ng I; Schneider AG
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010480. PubMed ID: 25758322
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
